GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TSB Grant to Develop Dementia Diagnosis Products

13 Dec 2013 07:00

RNS Number : 4517V
IXICO plc
13 December 2013
 



 

IXICO Awarded Technology Strategy Board Grant to Support the Development of Dementia Diagnosis Products

 

13 December 2013, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has been awarded a Stratified Medicine Grant by the UK's innovation agency, the Technology Strategy Board to provide funding to support the development of products to address the global dementia challenge.

 

The grant has been awarded under the Technology Strategy Board's recently launched 'Advancing In-Vivo Imaging for Stratified Medicine' competition. 

 

For this project, a consortium led by IXICO, which includes Imperial College, London as a research partner, Medimmune Limited (the global biologics research and development arm of AstraZeneca) and a second leading global pharmaceutical company as commercial partners, will apply a machine learning framework to a unique combination of reference data to develop a digital dementia prognosis tool. This will use commonly collected diagnostic information (including MRI scans and cognitive, functional and demographic data) to stratify patients based on their expected rate of decline. This could help with the diagnosis of dementia in the clinic and also with the enrichment of patient populations enrolled in clinical trials of investigational drugs, potentially improving the likelihood of measuring a therapeutic effect.

 

Several further global pharmaceutical companies have expressed interest joining the project as collaborators, and contributing clinical trial data in due course. The total value of the 24 month research project is approximately £1 million. The value of the grant is £633,962 of which £456,956 is allocated to IXICO and the remainder to Imperial College. The pharmaceutical partners and collaborators are contributing scientific resources from their R&D teams and access to data from completed clinical trials.

 

This brings the total grant funding secured by IXICO in the last 18 months to approximately £2.6 million of which approximately £2.4 million remains to be drawn down by IXICO.

 

This week the Technology Strategy Board features IXICO, the "Dementia Champions", as its Success Story www.innovateuk.org/success-stories detailing a funding story that stretches back 5 years.

 

Professor Derek Hill, Chief Executive of IXICO commented: "We are pleased to have been awarded this Technology Strategy Board grant. IXICO's products and services are focused on three overlapping areas within clinical trials, experimental medicine and diagnostics; the scope of this project will benefit our work in each. We look forward to working with Imperial and our commercial collaborators to develop important tools with the potential to improve clinical diagnosis of dementia and accelerate the development of effective treatments for Alzheimer's disease."

 

 

Enquiries

 

IXICO plc

+44 207 691 2064

Derek Hill, CEO

Charles Spicer, VP Corporate Development

 

Peel Hunt LLP (Nominated Adviser and broker)

+44 207 418 8900

James Steel

Vijay Barathan

Harry Florry

 

FTI Consulting Limited (U.K. Investor Relations)

+44 207 831 3113

John Dineen

Simon Conway

 

 

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and being readied for launch into the wider clinical diagnostic market. Since incorporation, IXICO has been contracted by seven of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

 

About the Technology Strategy Board

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMMZZZRGFZZ
Date   Source Headline
16th Jan 20083:38 pmRNSAnnual Report and Accounts
10th Jan 20082:29 pmRNSDirector/PDMR Shareholding
2nd Jan 200811:38 amRNSTotal Voting Rights
14th Dec 20071:14 pmRNSDirector/PDMR Shareholding
4th Dec 200712:38 pmRNSTotal Voting Rights
29th Nov 20074:40 pmRNSSecond Price Monitoring Extn
29th Nov 20074:35 pmRNSPrice Monitoring Extension
29th Nov 20077:01 amRNSFinal Results
27th Nov 200711:56 amRNSHolding(s) in Company
26th Nov 20074:35 pmRNSPrice Monitoring Extension
23rd Nov 200711:14 amRNSAppointment of Advisor
9th Nov 200712:53 pmRNSDirector/PDMR Shareholding
29th Oct 20073:37 pmRNSBlock Listing Cancellation
29th Oct 20073:37 pmRNSAdditional Listing
3rd Oct 20079:58 amRNSNew Accounting Ref Date
24th Sep 20077:02 amRNSRe Agreement
18th Sep 200711:39 amRNSBlocklisting Interim Review
14th Sep 20078:55 amRNSDirector/PDMR Shareholding
14th Sep 20078:55 amRNSDirector/PDMR Shareholding
6th Aug 20074:34 pmRNSDirector/PDMR Shareholding
6th Aug 20074:32 pmRNSDirector/PDMR Shareholding
30th Jul 20077:00 amRNSResearch Update
26th Jun 20077:02 amRNSRe Agreement
20th Jun 20077:00 amRNSBoard Change
14th Jun 20073:02 pmRNSResult of EGM
11th Jun 200711:56 amRNSHolding(s) in Company
7th Jun 200712:13 pmRNSDirector/PDMR Shareholding
5th Jun 20077:02 amRNSResearch Update
22nd May 20079:41 amRNSNotice of EGM
17th May 20077:01 amRNSResearch Update
9th May 20072:49 pmRNSDirector/PDMR Shareholding
9th May 20072:49 pmRNSDirector/PDMR Shareholding
9th May 20072:43 pmRNSDirector/PDMR Shareholding
9th May 20072:40 pmRNSDirector/PDMR Shareholding
1st May 20071:36 pmRNSBlocklisting Interim Review
1st May 20077:02 amRNSInterim Results
24th Apr 20074:37 pmRNSPrice Monitoring Extension
20th Apr 200711:26 amRNSNotice of Results
16th Apr 20077:01 amRNSProduct Launch
2nd Apr 20077:01 amRNSTotal Voting Rights
29th Mar 20079:36 amRNSResult of AGM
26th Mar 20077:12 amRNSProduct Launch
19th Mar 200711:45 amRNSBlocklisting Interim Review
7th Mar 20073:15 pmRNSHolding(s) in Company
7th Mar 20072:50 pmRNSHolding(s) in Company
2nd Mar 20072:25 pmRNSAGM Notification
1st Mar 20074:41 pmRNSSecond Price Monitoring Extn
1st Mar 20074:39 pmRNSPrice Monitoring Extension
1st Mar 20073:37 pmRNSPlacing
15th Jan 20074:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.